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T cellsGenetic and environmental factors jointly determine the susceptibility to develop Multiple Sclerosis (MS).
Collaborative efforts during the past years achieved substantial progress in deﬁning the genetic architecture,
underlying susceptibility to MS. Similar to other autoimmune diseases, HLA-DR and HLA-DQ alleles within
the HLA class II region on chromosome 6p21 are the highest-risk-conferring genes. Less-robust susceptibility
effects have been identiﬁed for MHC class I alleles and for non-MHC regions. The role of environmental risk
factors and their interaction with genetic susceptibility alleles are much less well deﬁned, despite the fact
that infections have long been associated with MS development. Current data suggest that infectious triggers
are most likely ubiquitous, i.e., highly prevalent in the general population, and that they require a permissive
genetic trait which predisposes for MS development. In this review article, we illustrate mechanisms of
infection-induced immunopathologies in experimental animal models of autoimmune CNS inﬂammation,
discuss challenges for the translation of these experimental data into human immunology research, and
provide future perspectives on how novel model systems could be utilized to better deﬁne the role of viral
pathogens in MS.unology, Clinical Immunology
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Multiple sclerosis (MS) is a chronic inﬂammatory disease of the
central nervous system (CNS) which usually begins in early adulthood
and is characterized by tissue inﬂammation, demyelination and
gliosis, various degrees of axonal pathology, and episodic or pro-
gressive neurological disability. More than 1.5 million people world-
wide and at least 400,000 individuals in Europe alone are affected by
MS, which is second only to trauma as a cause of acquired disability in
young adults in most Caucasian populations [1].
Genetic and environmental factors jointly determine the suscep-
tibility to develop MS. Collaborative efforts during the past years
achieved substantial progress in identifying genetic risk factors that
predispose for MS [2]. HLA-DR and HLA-DQ alleles of the HLA class II
region on chromosome 6p21 are the highest-risk-conferring genes for
most major autoimmune diseases including MS which is particularly
associated with the DRB1*1501 allele encoding HLA-DR2b. Less-
robust susceptibility effects have been identiﬁed for MHC class I
alleles and in non-MHC regions. The role of environmental as opposed
to genetic risk factors in MS is much less well deﬁned, despite the fact
that infections have long been thought to critically contribute to
disease development. In 1894, Pierre Marie, a former student of
Charcot, argued strongly that infection was the cause of multiplesclerosis. He felt that infectious pathogens, or more likely combined
infections, initiate MS [3]: “These gentlemen, are suppositions, and I
put them before you without unreasonably insisting upon them. The
one point in this discussion which I would ﬁx in your minds is the
following fact, a fact, thank God, has been well established, viz., that
the cause of insular sclerosis in intimately connected with infectious
diseases.” More than a century later, intriguing epidemiological but
weak immunological and virological evidence has resulted in a
bewildering list of usual suspects including measles, rabies, scrapie-
like agent, Carp agent, paramyxovirus, coronavirus, Epstein–Barr
virus, herpes zoster, herpes simplex virus, human herpesvirus 6,
rubella, mumps, canine distemper, Marek's Semliki forest virus,
animal and human retroviruses, and human T-cell lymphoma virus
type I. Almost universally, these associations have later not withstood
scrutiny. Such unclarity and vagueness spurred the notion that a
pathogenic role of infectious agents in MS cannot be established
unless experiments provide unequivocal evidence that the postulates
of Koch have been met.
Traditionally, microbiologists have used postulates formulated by
Robert Koch and Friedrich Loefﬂer to demonstrate whether a
particular microbe causes a speciﬁc disease: a microorganism must
be (1) found in abundance in all organisms suffering from the
disease, but should not be found in healthy animals; a microorgan-
ism must be (2) isolated from the host with the disease and grown
in pure culture; (3) the speciﬁc disease must be reproduced when a
pure culture of the microbe is inoculated into a healthy susceptible
host; and (4) the pathogen must be recoverable from the
experimentally infected host [4]. These postulates retain historical
importance, but fulﬁllment of all four postulates is not required to
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applied these criteria in the 19th century to establish the etiology of
tuberculosis, but he abandoned the universalist requirement of the
ﬁrst postulate when he discovered asymptomatic carriers of cholera
[5]. Likewise, not all individuals exposed to Mycobacterium tubercu-
losis become infected, and progression towards clinical tuberculosis
is far from an inevitable consequence of infection with M.
tuberculosis, since only ∼10% of the vast number of infected
individuals actually develop clinical disease [6]. Such observations
led to the development of the ﬁeld of human genetics of infectious
diseases and the identiﬁcation of genetic traits that predispose to
infection and clinical disease development [7]. The insight that
clinical infectious diseases result from complex interactions between
the infectious agent, the environment, and host factors rather than
following a simple ‘one organism–one disease paradigm’ has
implications for our understanding of how infectious pathogens
might trigger complex autoimmune diseases such as MS. Current
data suggest that infectious agents that contribute to MS develop-
ment are most likely ubiquitous and highly prevalent in the general
population. Moreover, they require a permissive genetic trait that
determines the susceptibility of the host to develop MS. Finally, the
distinct conditions, under which primary infection with these
pathogens is encountered, might further modulate disease risk.
Here, we review new data for an association of certain infectious
pathogens with MS and illustrate mechanisms of infection-induced
immunopathologies in experimental animal models of autoimmune
CNS inﬂammation.
2. Multiple sclerosis: genes and environment
MS is a relatively common disease in Europe, the United States,
Canada, New Zealand, and parts of Australia, and its prevalence
generally follows a north to south gradient on the Northern
Hemisphere and the opposite on the Southern Hemisphere with
very low rates or virtually absence of the disease near the equator.
This geographic distribution can be attributed to both genetic effects
and environmental inﬂuences. Arguing for the genetic hypothesis,
the prevalence of MS differs strikingly between geographically close,
but genetically distinct populations. Ethnic groups like Lapps in
Scandinavia, Gypsies in Hungary, Maoris in New Zealand, or
Aborigines in Australia are rarely or virtually not affected by MS,
although the disease is otherwise common in these latitudes.
Similarly, MS is rare among Japanese, Chinese, African Blacks,
North and South Amerindians, and the native population in southern
countries of the former Soviet Union, but occurs notably more
frequently among Caucasians living in the same area. Further
examples are the different prevalence rates in genetically distant
populations living on the same island as it has been reported for
Sardinia, Cyprus, and Ireland [8].
Familial aggregation studies including twins, siblings, and adop-
tees demonstrated that the risk to develop MS increases with the
degree of relatedness between individuals. For example, monozygotic
twins of patients with MS have a more than 100 times higher risk to
develop the disease and full-siblings have an approximately 20 times
increased lifetime risk compared to the general population [9,10].
While these recurrence risk values are considerably lower than the
ones for a Mendelian-dominant disorders such as Huntington's
disease (approximately 5000-fold increased risk for siblings), they
are similar to the risks that have been reported for other complex
polygenic diseases such as type 1 diabetes (approximately times 20
increased risk for siblings).
An elegant approach to dissect the impact of genetic sharing
versus a shared family environment for the development of MS are
epidemiological studies on adoptees (no shared genes) and half-
siblings compared to full-siblings (25% and 50% shared genes,
respectively). Adopted relatives, although raised from infancy withthe MS patients, do not develop MS more frequently than it would
be expected for the general population [9]. Half-siblings raised
apart (different environments) or together (same environment)
with MS patients have similar risk to develop the disease and, the
recurrence risk for half-siblings is signiﬁcantly lower than that for
full-siblings raised in the same family (1.32% vs. 3.46%) [10].
These studies made clear that the excess of the disease in
biological relatives results from the sharing of genetic material,
but does not follow a simple Mendelian mode of inheritance.
Another important conclusion that can be drawn from these
observations is that any nongenetic, environmental factor is likely
to be ubiquitous and not conﬁned to the family microenviron-
ment [11].
The concordance rate for MS is approximately 25–30% for
monozygotic and 2–5% for dizygotic twins. Although studies on
animal models of autoimmune disease demonstrated that the rate
of disease expression can be titrated by the number of disease-
associated genes under identical environmental inﬂuences [12],
indicating that a simple concordance rate does not optimally
reﬂect and might, indeed, underestimate the contribution of
genetic factors to autoimmune disease development, the fact that
most monozygotic twins are discordant for MS clearly points
towards an important role of environmental factors in the
evolution of MS.
Environmental contributions are further supported by migration
studies. The incidence of MS in migrants tends to be intermediate
between that of their birthplace and that of their ﬁnal residence
and close to the latter when migration occurs in childhood [13]. As
pointed out by Ascherio and Munger [13], the risk to develop MS
declines among individuals migrating from high- to low-prevalence
areas [14–16] but does not consistently increase with migration in
the opposite direction. As an example, ﬁrst-generation immigrants
from the Caribbean and Asia whose genetic susceptibility is proven
by the high rates of MS among their UK-born children [17,18]
rarely develop MS themselves, suggesting that individuals born in
low-risk areas appear to beneﬁt from some long-lasting protection
that is, however, not transmitted to their children [13].
Taken together, familial aggregation and migration studies
indicate that exposure to environmental factors in childhood, and
possibly during adult life, appear to be strong determinants of MS
risk. The nature of such trigger factors could be both infectious
and noninfectious. In this review, we focus on mechanisms of
infection-induced pathology in MS.
3. Mechanisms
Several mechanisms have been proposed to explain how patho-
gens such as viruses might trigger autoreactive immune responses in
MS. These include virus-induced general activation of the immune
system and the provision of viral gene products that speciﬁcally
stimulate immune responses which cross-react with self-antigen
(Fig. 1).
3.1. Mechanisms of bystander activation
Infectious agents express speciﬁc pathogen-associated molecular
patterns (PAMPs). These are recognized by immune cell receptors
leading to cellular activation, which increases the antigen-presenting
capacity and the expression of costimulatory molecules by antigen-
presenting cells (APCs), as well as their production of type I
interferons, pro-inﬂammatory cytokines and chemokines, which in
turn initiate and direct the immune response against the invading
pathogen. Thus, pathogens are recognized as adjuvants for the
immune response against them and could, via pattern recognition
receptor (PRR)-mediated activation of APCs that contain self-antigens
obtained from dying cells or tissue damage, activate autoreactive T
Fig. 1. Molecular mechanisms of pathogen-induced autoimmunity. (A) Pathogen-activated antigen-presenting cells can display self-antigens from dying cells to autoreactive T
lymphocytes in a process known as bystander activation. (B) Activation of the immune system resulting from stimulation of pattern recognition receptors by infectious agents can
lead to expression of proinﬂammatory mediators and triggering of autoreactive lymphocytes. (C) Microbial superantigens cross-link MHC class II molecules with TCRs inducing
antigen unspeciﬁc activation of autoreactive T cells. (D) Certain pathogen-derived antigens share structural similarities with self-peptides causing activation of autoreactive T cells
throughmolecular mimicry. (E) The process of epitope spreading can enhance autoimmune responses by activating autoreactive T cells to ‘new’ self-antigens during the progression
of the disease. (F) Viral agents can enhance the activation state of autoantigen presenting cells and induce the survival of autoreactive lymphocytes. As an example, persistent
infection of microglial cells with Theiler's murine encephalomyelitis virus (TMEV)was shown to upregulate expression ofMHC and co-stimulatory molecules and enhance the ability
of these cells to function as effective APCs [34]. Furthermore, EBV infection could assist in the survival of autoreactive B cells [36]. APC, antigen-presenting cell; MHC, major
histocompatibility complex; PAMP, pathogen-associated molecular pattern; TCR, T-cell receptor; TLR, Toll-like receptor.
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infection could facilitate activation of autoreactive bystander T and B
cells via proinﬂammatory cytokine production. An even broader form
of bystander activation is achieved by microbial superantigens, which
cross-link MHC class II molecules with TCRs that contain a certain Vβ
domain, leading to T-cell activation independently of speciﬁc antigen
recognition. Staphylococcal, mycoplasma, endogenous retrovirus-
derived, and enteric microbiota-generated superantigens were sug-
gested to be involved in the disease exacerbation in animal models of
MS [19].
3.2. Mechanisms of molecular mimicry
Polyspeciﬁc antigen recognition has emerged as a fundamental
feature of adaptive cellular immune responses. Mathematical modelsindicated that the TCR repertoire is not large enough to give functional
protection against all possible foreign epitopes on the basis of a one
TCR–one epitope model, and several groups consistently demonstrat-
ed that there can be considerable ﬂexibility in TCR recognition of
peptide–major histocompatibility complex (MHC) complexes [20–
24]. Polyspeciﬁc or so-called degenerate TCR recognition is considered
to represent a compromise between the need to provide host
protection against virtually any pathogen-derived epitope and, at
the same time, the need to ensure thymic positive selection and
peripheral maintenance of this T-cell repertoire via intermediate
afﬁnity recognition of self-peptides that are presented by self-MHC
molecules. Such degenerate speciﬁcity, however, also carries a certain
risk for autoimmunity under special circumstances, e.g., strong innate
immune activation. It has previously been shown in a number of
animal models transgenic for human autoreactive T-cell receptors
Table 1
Viral agents suspected as triggers of multiple sclerosis.
Virus Evidence for association Reference
Herpesviruses
VZV Acquired earlier in life by MS patients [107]
Reactivation linked to MS exacerbation [108]
Viral DNA isolated from blood and CSF [48]
Virions observed by electron microscopy in CSF
(inconsistent observations)
[49,50]
HHV-6 Isolated from blood, CSF, and brain tissue [54,55]
Presence of antiviral antibodies in blood and CSF
(inconsistent observations)
[56,57]
Increased viral loads linked to MS exacerbation [58,59]
Cross-reactivity between virus-speciﬁc T cells and
myelin antigens
[62,63]
EBV Near-absolute seropositivity in children and adults
with MS
[71–73]
Increased risk of MS in individuals with history of
infectious mononucleosis
[65,66,69]
Virus reactivation linked to disease activity in early MS [109]
Increased EBNA1-speciﬁc antibodies before MS onset [75,74,76]
Cross-reactivity of clonally expanded EBNA1-speciﬁc T
cells with myelin antigens
[80,81]
Enrichment of EBV-infected B cells in MS brain tissues [83]
Retroviruses
HERV-W
(MSRV)
Isolated from blood and CSF of MS patients [90,91]
Encode for proteins with superantigenic activity [93]
Chromosomal loci identiﬁed as MS-susceptibility
regions
[95,96]
Virions trigger acute neurological symptoms in mice [94]
Other agents
Torque
Teno virus
Clonally expanded T cells from CSF of MS patients
recognize viral motifs
[103]
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isms of molecular mimicry [25–27].
3.3. Mechanisms of epitope spreading
In addition to one TCR being engaged by different MHC/peptide
complexes, one TCR speciﬁcity can set free epitopes for other TCRs and
result in a process called epitope spreading. Epitope spreading
describes the phenomenon observed in animal models of autoim-
mune diseases and cancer patients in which responses to immuno-
dominant epitopes are elicited ﬁrst, followed by responses to less
dominant epitopes [28–32]. Although these examples document
epitope spreading within autoantigens and to additional autoanti-
gens, the inﬂammatory environment of viral infections could also
support these immune response cascades by increasing the presen-
tation of autoantigens, thereby spreading immune responses from
foreign to self-antigens.
3.4. Emerging mechanisms
The mechanisms of bystander activation, polyspeciﬁc antigen
recognition/molecular mimicry, and epitope spreading are not the
only ways by which pathogens might trigger or accelerate CNS
autoimmunity. Viral infections could also directly maintain auto-
reactive effector T cells or autoantigen-presenting cells. For example,
Theiler's murine encephalomyelitis virus (TMEV)-induced demyelin-
ating disease (TMEV-IDD) is a model of MS in which intracerebral
TMEV infection of mice leads to an autoimmune demyelinating
disorder 30–40 days after infection [33]. Persistent infection of
microglial cells with TMEV has been shown to upregulate expression
of MHC and costimulatory molecules and to enhance the ability of
these cells to function as effective APCs [34]. Furthermore, Epstein–
Barr virus (EBV) immortalizes B cells and assists in their differenti-
ation into long-lived memory B cells. These mechanisms could
support the survival of autoreactive B cells or of a reservoir of APCs
that can present autoantigens to promote autoimmunity [35,36].
The evidence for a biological role of these mechanisms mainly
stems from experimental autoimmune disease models. Testing
whether these mechanisms are indeed relevant in human autoim-
mune diseases such as MS is challenging because og a number of
reasons including the following:
1. Chronic autoimmune diseases are likely to become clinically
apparent only after a considerable period of subclinical autoreac-
tivity, at which time the pathogenmight have already been cleared
and/or the antiviral immune responses might have subsided.
2. The proposed mechanisms by which a pathogen or a number of
pathogens potentially initiate and sustain MS are likely dynamic,
not mutually exclusive and might occur simultaneously or
sequentially. A simple ‘one organism–one disease’ or ‘one mech-
anism–one disease’ paradigm might not apply to complex and
heterogeneous diseases such as MS.
3. The ﬂip side of the idea that autoimmunity is driven by viral
infections is that autoreactive immune responses, or even only a
predisposition to the development of these responses, might affect
the ability of the host to control infections and to regulate antiviral
immune responses. The latter probably accounts for the occurrence
of polyspeciﬁc antiviral humoral immune responses in the
cerebrospinal ﬂuid (CSF) compartment in patients with MS,
which are characterized by intrathecal synthesis of IgG antibodies
towards a variety of viruses including measles, rubella, varicella
zoster virus, and the human herpesvirus 6 [37–41]. Intrathecal
humoral immune response against measles, rubella, and varicella
zoster virus (MRZ reaction, MRZR) is present in 80–100% of
patients with MS but less common in acute inﬂammatory diseases
of the CNS [41]. Although these alterations could potentially beused as surrogate disease markers for diagnostic purposes, there is
no evidence that they contribute to the initiation and progression
of CNS tissue damage in MS [42].
The argument that infections contribute to disease development is
strong for autoimmune conditions associated with one or two speciﬁc
infectious agents such as Guillain–Barré syndromewhich is frequently
preceded by Campylobacter jejuni infection or rheumatic fever after
streptococcal infection. In contrast, MS as well as other major
autoimmune diseases has been associatedwith a number of infectious
agents. The ones that have received most attention during the past
years are discussed below (Table 1).
4. Herpesviruses
Herpesviruses represent a group of large DNA viruses that are
capable of establishing latency with potential for reactivation after
primary infection, which typically occurs in childhood. Upon
transmission to a naive host, the virus ﬁrst ampliﬁes the viral load
through replicative (lytic) infection, then persists for the life of the
host as an asymptomatic latent infectionwith occasional reactivations
into lytic cycle, producing infectious virions transmissible to a new
host. The mutual coexistence of human herpesviruses whether of the
alpha [herpes simplex virus (HSV) types 1 and 2, varicella–zoster
virus], beta [cytomegalovirus (CMV) and human herpesviruses 6 and
7], or gamma [Epstein–Barr virus (EBV) and Kaposi's sarcoma–
associated herpesvirus (KSHV)] subfamilies with their host depends
on its ability to mount an appropriate virus-speciﬁc immune
response, since most herpesvirus-associated diseases involve situa-
tions in which host responses either have been seriously compro-
mised or have been unusually hyperactivated by the viral challenge
[43]. Infection with VZV, HHV-6, and EBV has particularly been
associated with MS.
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VZV is the causative agent of chickenpox, acquired by 95% of adults
in the developedworld [44]. The virus establishes latency in the dorsal
ganglia of most healthy people [45], while zoster is the result of
symptomatic viral reactivation that affects about 1% of the general
population [46]. Although many epidemiological studies link VZV to
MS, a report evaluating 40 studies in the period 1965–1999 indicated
that there is insufﬁcient evidence to support the association of MS
with varicella or zoster infections [47]. Recent studies conducted by
Sotelo et al. [48] indicated the presence of VZV DNA in CSF and
mononuclear blood cells of MS patients in relapse, while VZV viral
particles were observed by electron microscopy in patients' CSF [49].
Conversely, another study failed to show the presence of VZV virions
or DNA in the CSF or in the acute plaques of MS patients [50].
Furthermore, recombinant antibodies prepared from clonally ex-
panded plasma cells in MS CSF, which are thought to represent the
intrathecally synthesized oligoclonal IgG, did not bind to VZV-infected
cells [50]. Therefore, the role of VZV in MS remains controversial, and
further studies with more rigorous methodologies are required to
support the environmental role of VZV as a trigger of MS.
6. Human herpesvirus-6
Research on HHV-6 involvement in MS has also been contradictory.
This lymphotrophic herpesvirus, isolated in 1986 from patients
with lymphoproliferative disorders [51], exhibits predominantly CD4+
T-lymphocyte tropism but has a tendency to infect neural cells, which
renders it a potential suspect in the pathology of many neurological
disorders [52]. Two virus variants have been identiﬁed, HHV-6B,
associated with mesial temporal lobe epilepsy (MTLE), and HHV-6A,
which has primarily been associated with MS [53].
DNA from HHV-6A was detected in brain tissue, serum, and CSF of
some MS patients [54–57]. Exacerbation of relapsing-remitting MS
has been linked to higher viral loads in serum [58,59] and in
peripheral blood mononuclear cells (PBMCs) [60], suggesting associ-
ation of HHV-6 reactivation with disease relapses. This hypothesis is
supported by observations of increased viral DNA and antigen levels
in MS brain tissues [58]. Other reports suggested that constitutive
presence of active HHV-6 infection in glial cells in inﬂamed CNS tissue
could result in virus-triggered immunopathologies in MS [61].
A mechanism of molecular mimicry of the virus-encoded U24
protein and myelin basic protein (MBP), a putative MS-associated
autoantigen, has been proposed based on amino acid sequence
homology [62]. Although cross-reactive T cells were identiﬁed in MS
patients, they were also observed to a lower frequency in controls [63].
Taken together, epidemiological data and the presence of active HHV-6
infection in someMS brain samples suggest a possible role for HHV-6 in
perpetuating tissue damage in MS.
7. Epstein–Barr virus
Another widespread herpesvirus is EBV (or HHV-4), which causes
asymptomatic primary infection in early childhood or if acquired later
in life, leads to infectious mononucleosis (IM) in up to 25% of cases
[64]. The virus establishes latency in B cells and is notorious for its
tumorigenic potential. However, since the immune system constrains
viral replication, malignancies occur mostly in cases of immunosup-
pression or of immunodeﬁciencies [43].
Evidence for a potential role of EBV in the development of MS arises
from reports on the positive correlation between clinical history of IM
and MS occurrence [65,66]. The risk of MS has been suggested to
increase after IMand to persist for at least 30 years after infection [67]. A
recentmeta-analysis reviewed 14 studies, 11 case–control and 3 cohort
studies, which investigated the association of IM and MS. The analysis
concluded that the combined relative risk for development of MS afterIM was 2.3 and in HLA-DR2-positive individuals even 7 [68], indicating
that symptomatic EBV infection is a risk factor for MS [69]. These
observations were conﬁrmed by Ramagopalan et al. who compared
more than 14,000MS cases and 7000 spouse controls. Their study found
a positive correlation of MS disease with history of IM, while no such
association was observed for history of symptomatic measles, mumps,
rubella, and varicella infections, or with history of measles, mumps,
rubella, hepatitis B, and inﬂuenza vaccination [70].
Serological studies have demonstrated almost absolute, close to
100%, EBV seropositivity in MS patients. However, high seropositivity,
ranging between 90% and 95%, is also detected in the healthy adult
population. A more prominent difference in seropositivity was
observed in children with MS, 83% of which were reported to be
seropositive for EBV, compared to 42% of healthy age-matched
controls [71]. Moreover, no signiﬁcant difference in seropositivity
was observed between the two groups for cytomegalovirus,
parvovirus B19, and VZV. These results were conﬁrmed by a German
study, showing 98.6% EBV seropositivity in children with MS in
contrast to 72.1% in age-matched healthy controls [72]. Comparable
results were observed by a more recent study that identiﬁed
broadened and augmented recognition of the latency-associated
EBV nuclear antigen 1 (EBNA1), suggesting dysregulation of EBV-
speciﬁc immune responses in pediatric MS [73].
An age-dependent relationship was suggested between alterations
in EBV-speciﬁc immune responses and clinical manifestation of MS
[74]. A longitudinal study in 69 matched case–control sets of US
military personnel investigated the presence of EBV antibodies before
MS onset. While EBV-speciﬁc antibody titers were similar between
cases and people who developed MS before the age of 20, a two- to
threefold increase in EBV-speciﬁc antibody titers was observed in MS
cases after the age of 25. The strongest risk factor, rising MS
susceptibility tenfold, were increased titers of serum antibodies to
EBV-derived nuclear antigens (EBNA) and, in particular, to the EBV
nuclear antigen-1 (EBNA1) [74,75]. A recent study conﬁrmed these
results by reporting that EBNA1-speciﬁc antibody responses occurred
15 to 20 years before onset of symptoms inMS patients [76]. Although
these observations suggest an EBV-speciﬁc immune dysregulation
preceding MS onset, a limitation of the abovementioned studies is
that they compared EBV-speciﬁc responses only to HCMV responses
and not to those towards other viruses, suspected in MS association.
A more recent study determined immune responses to EBV, HHV-
6, human cytomegalovirus (HCMV), inﬂuenza virus, andmeasles virus
antigens in a cohort of 147 patients with clinically isolated syndromes
suggestive of MS (CIS) with a mean follow-up of 7 years compared to
50 demographically matched controls [77]. CIS patients showed
increased humoral and cellular immune responses to EBNA1 but not
to other EBV-derived proteins. IgG responses to other viral antigens
and frequencies of T cells speciﬁc for HCMV and inﬂuenza virus gene
products were unchanged in CIS patients. Furthermore, EBNA1 was
the only viral antigen with which immune responses correlated with
number of clinical disability and MRI metrics during the follow-up
period and increased EBNA1-speciﬁc IgG responses in CIS patients
predicted conversion to clinically deﬁnite MS. Higher IgG responses to
EBNA1 in patients with CIS and relapsing-remitting MS (RRMS) were
also reported to correlate with increased frequencies of EBV-speciﬁc
CD8+ T cells [78]. In line with the results of the former study, Farrell et
al. [79] found higher immunoglobulin G (IgG) responses to EBNA1 in
CIS and RRMS patients, whereas responses to lytic EBV capsid
antigens, HCMV, and measles-virus encoded proteins were un-
changed compared to healthy blood donors. In these patients,
elevated EBNA1-speciﬁc IgG responses were associated with the
development of gadolinium-enhancing (Gd+) lesions and predictive
for T2 lesion volume change and clinical disability for a period of
5 years [79].
EBNA1 is the most consistently recognized EBV-speciﬁc antigen,
which stimulates CD4+ T-cell responses in healthy virus carriers.
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patients [80,81]. Moreover, a small subset of them have been shown to
cross-react with myelin antigens, supporting the hypothesis that
clonally expanded EBNA1-speciﬁc T cells could be actively involved in
MS immunopathology by stimulating cross-recognition through mo-
lecular mimicry [81].
Molecular mimicry is one of the classical paradigms for infection-
induced autoimmunity and there is solid evidence form a number of
animal models transgenic for human autoreactive T-cell receptors
that microbial peptides can induce MS-like disease through mechan-
isms of molecular mimicry [25–27]. An alternative hypothesis for the
association of EBV infection and autoimmune diseases is based on the
virus' ability to immortalize B cells and to assist in their differentiation
into long-livedmemory B cells. Indeed, there is evidence that the EBV-
encoded proteins LMP1 and LMP2 mimic signals of T-cell help and B-
cell receptor engagement, respectively, possibly rendering autoreac-
tive B cells less susceptible to tolerance control in the periphery [82].
These mechanisms could support the survival of autoreactive B cells
or of a reservoir of APCs that can present autoantigens to promote
autoimmunity [35,36].
B cells are now recognized to play a critical role in the
pathogenesis of MS, and an increasing number of compounds that
deplete B cells or target pathways essential for B-cell development
and function are currently being tested for their potential use as MS
therapeutics. Seraﬁni et al. [83] found that EBV-infected B cells
expressing viral antigens are signiﬁcantly enriched in postmortem
brain samples from patients with MS, but not in brain samples from
patients with other inﬂammatory CNS diseases. Activated CD8+ T
cells were also present close to EBV-infected B-cell foci, suggesting
that EBV-speciﬁc lymphocyte responses may be involved in MS
immunopathologies. However, these ﬁndings could not be repro-
duced in several subsequent studies [84–86]. Further research
should clarify the source of this discrepancy. At present, the
aforementioned conﬂicting data on the presence of EBV in MS
brain tissue do not allow to draw deﬁnite conclusions on the
frequency and potential function of EBV-infected B cells in the CNS
of patients with MS.
Taken together, there is strong epidemiological evidence for a link
between symptomatic EBV infection and MS development. The
immune-modifying function of EBV suggests that this virus is, indeed,
a major candidate for triggering MS. The mechanisms responsible for
this association are, however, far from understood.
8. Human endogenous retroviruses
Human endogenous retroviruses (HERVs), comprising about 8% of
the human genome, are remnants of ancestral germ line infections by
retroviruses [87]. A founding member of the HERV-W family, known
as MS-associated retroviral agent (MSRV), is presumably a complete
replication-incompetent virus capable of forming extracellular infec-
tious virions [88,89]. MSRV has been repeatedly isolated from CSF and
blood of MS patients [90,91], as well as from body ﬂuids of individuals
with other neuroinﬂammatory disorders, but is less frequently
observed in healthy controls [92]. Notably, MSRV has been shown to
encode a protein that displays pro-inﬂammatory and superantigenic
activity for CD4+ T cells [93]. The immunopathogenicity of activated T
cells was conﬁrmed in an in vivo study, in which severe combined
immunodeﬁciency (SCID) mice with engrafted human immune
system components were injected with MSRV virions and presented
with acute neurological symptoms [94].
Interestingly, the HERV-W provirus is located on chromosome
14q11.2 region within a T-cell α/β-receptor, whereas a different
HERV-H family provirus, also expressed in cells of MS patients [95], is
located on chromosome 7q21-22 region. These two chromosomal
regions correspond to genetic loci that have been associated with
predisposition to MS [96].In addition, a study by Sutkowski et al. [97,98] reported that the
env gene of HERV-K18, possessing superantigenic activity, was
transcriptionally activated by EBV. These observations suggest that
superantigen-stimulated T-cell activation could potentially have a
role in EBV infection and associated diseases. There is increasing
interest in the study of HERVs as causal factors in MS. Recent ﬁndings
identify herpesviruses, including EBV and HHV-6 [99,100], as
potential inducers of HERV activation, alluding to the involvement
of more than one infectious agent as triggers of MS. However, more
studies are needed to conﬁrm this hypothesis.
9. Torque Teno virus
Not only pathogenic but also nonpathogenic infectious agents
have been suggested to be involved in exacerbation and/or induction
of MS. The Torque Teno virus (TTV), claimed to have a prevalence rate
of 72–100% in the general population [101], has been shown to
establish persistent infection without signiﬁcant clinical phenotype
[102]. A study by Sospedra et al. [103] determined the speciﬁcity of
clonally expanded T cells from CSF of MS patients during disease
exacerbation. These T cells were shown to recognize poly-arginine
regions of TTV as well as evolutionary conserved motifs of other
common viruses and prokaryotes, suggesting a mechanism of
misdirected autoantigen response as a result of molecular mimicry.
However, due to the paucity of data, the relation of TTV infection and
MS remains ill deﬁned.
10. Conclusions and future perspectives
The relationship between infections and autoimmune diseases is
complex and the mechanisms by which infectious pathogens could
trigger MS are likely dynamic, i.e., they might change over time and
not be mutually exclusive. Epidemiological observations indicate that
viral infections could contribute to MS development not only as
triggers of disease exacerbations but also as etiological agents, i.e.,
long before the disease becomes clinically apparent. The two- to
three-folds increased risk of developing MS among individuals with
history of IM compared with subjects who acquired EBV without
symptoms, the almost universal seropositivity for EBV in adults and
children with MS, and the steep and monotonic increase in MS risk
with increasing titers of antibodies to EBV in apparently healthy
adults could suggest that EBV infection is causally linked to MS
development. The mechanisms responsible for this association are far
from understood. Moreover, the incidence of IM in Western countries
(≥5%) [64] exceeds the prevalence of MS in comparable populations
(0.1%) by far (more than 50-fold) suggesting that yet unidentiﬁed
genetic and/or additional environmental factors determine whether
symptomatic EBV infection indeed predisposes to MS.
Although one particular MS-causing agent might still be
discovered, current data suggest that multiple infections along
with noninfectious environmental factors trigger the development
of MS. These factors are likely ubiquitous, i.e., highly prevalent in
the general population, and they require a permissive genetic
background that predisposes for MS development. Future studies
investigating infectious pathogens in a complex and heterogenous
disease such as MS will beneﬁt from careful and detailed clinical,
pathological, and neuroimaging-based patient characterizations and
from reproducibility in different study populations. In addition,
novel humanized animal models of autoimmune diseases that are
simultaneously permissive for viral pathogens which usually infect
only humans [104,105] should allow investigation of speciﬁc aspects
of host–pathogen interactions during autoimmune CNS inﬂamma-
tion in vivo. The integration of these data might eventually allow us
to better deﬁne the role of viruses in the etiology and pathogenesis
of MS and how virus–host interactions could be targeted for MS
therapy [106].
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